Efficacy and Safety of Oral Tyrosine Kinase 2 Inhibitor PF-06826647 in Managing Moderate to Severe Plaque Psoriasis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study
J Am Acad Dermatol 2022 Apr 06;[EPub Ahead of Print], C Tehlirian, RSP Singh, V Pradhan, ES Roberts, S Tarabar, E Peeva, MS Vincent, JD GaleFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.